1. Home
  2. LGVN vs CWD Comparison

LGVN vs CWD Comparison

Compare LGVN & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.50

Market Cap

11.4M

Sector

Health Care

ML Signal

HOLD

Logo CaliberCos Inc.

CWD

CaliberCos Inc.

HOLD

Current Price

$1.41

Market Cap

10.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGVN
CWD
Founded
2014
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
11.4M
10.8M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
LGVN
CWD
Price
$0.50
$1.41
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$6.50
N/A
AVG Volume (30 Days)
423.0K
169.4K
Earning Date
11-04-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,437,000.00
$24,657,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$26.79
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$1.42
52 Week High
$2.24
$48.00

Technical Indicators

Market Signals
Indicator
LGVN
CWD
Relative Strength Index (RSI) 30.59 29.07
Support Level $0.52 $1.42
Resistance Level $0.55 $1.68
Average True Range (ATR) 0.03 0.10
MACD -0.00 0.03
Stochastic Oscillator 3.05 9.00

Price Performance

Historical Comparison
LGVN
CWD

About LGVN Longeveron Inc.

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

About CWD CaliberCos Inc.

CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.

Share on Social Networks: